These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 29266174)

  • 21. Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials.
    Ellingson BM; Gerstner ER; Smits M; Huang RY; Colen R; Abrey LE; Aftab DT; Schwab GM; Hessel C; Harris RJ; Chakhoyan A; Gahrmann R; Pope WB; Leu K; Raymond C; Woodworth DC; de Groot J; Wen PY; Batchelor TT; van den Bent MJ; Cloughesy TF
    Clin Cancer Res; 2017 Oct; 23(19):5745-5756. PubMed ID: 28655794
    [No Abstract]   [Full Text] [Related]  

  • 22. Leakage decrease detected by dynamic susceptibility-weighted contrast-enhanced perfusion MRI predicts survival in recurrent glioblastoma treated with bevacizumab.
    Hilario A; Sepulveda JM; Hernandez-Lain A; Salvador E; Koren L; Manneh R; Ruano Y; Perez-Nuñez A; Lagares A; Ramos A
    Clin Transl Oncol; 2017 Jan; 19(1):51-57. PubMed ID: 27026567
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer.
    Barata PC; Cooney M; Mendiratta P; Gupta R; Dreicer R; Garcia JA
    Invest New Drugs; 2019 Apr; 37(2):331-337. PubMed ID: 30402678
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
    Abou-Alfa GK; Blanc JF; Miles S; Ganten T; Trojan J; Cebon J; Liem AK; Lipton L; Gupta C; Wu B; Bass M; Hollywood E; Ma J; Bradley M; Litten J; Saltz LB
    Oncologist; 2017 Jul; 22(7):780-e65. PubMed ID: 28592620
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma.
    Field KM; Simes J; Nowak AK; Cher L; Wheeler H; Hovey EJ; Brown CS; Barnes EH; Sawkins K; Livingstone A; Freilich R; Phal PM; Fitt G; ; Rosenthal MA
    Neuro Oncol; 2015 Nov; 17(11):1504-13. PubMed ID: 26130744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.
    Vredenburgh JJ; Desjardins A; Herndon JE; Marcello J; Reardon DA; Quinn JA; Rich JN; Sathornsumetee S; Gururangan S; Sampson J; Wagner M; Bailey L; Bigner DD; Friedman AH; Friedman HS
    J Clin Oncol; 2007 Oct; 25(30):4722-9. PubMed ID: 17947719
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials.
    Ellingson BM; Harris RJ; Woodworth DC; Leu K; Zaw O; Mason WP; Sahebjam S; Abrey LE; Aftab DT; Schwab GM; Hessel C; Lai A; Nghiemphu PL; Pope WB; Wen PY; Cloughesy TF
    Neuro Oncol; 2017 Jan; 19(1):89-98. PubMed ID: 27580889
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The optimal regimen of bevacizumab for recurrent glioblastoma: does dose matter?
    Blumenthal DT; Mendel L; Bokstein F
    J Neurooncol; 2016 May; 127(3):493-502. PubMed ID: 26721244
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial.
    Moore KN; Sill MW; Tenney ME; Darus CJ; Griffin D; Werner TL; Rose PG; Behrens R
    Gynecol Oncol; 2015 Sep; 138(3):513-8. PubMed ID: 26171911
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single-agent Bevacizumab in Recurrent Glioblastoma After Second-line Chemotherapy With Fotemustine: The Experience of the Italian Association of Neuro-Oncology.
    Pasqualetti F; Pace A; Gonnelli A; Villani V; Cantarella M; Delishaj D; Vivaldi C; Molinari A; Montrone S; Pellerino A; Franchino F; Baldaccini D; Lombardi G; Lolli I; Catania F; Bazzoli E; Morganti R; Fabi A; Zagonel V; Bocci G; Fabrini MG; Rudà R; Soffietti R; Paiar F
    Am J Clin Oncol; 2018 Dec; 41(12):1272-1275. PubMed ID: 29782366
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma.
    Sepúlveda JM; Belda-Iniesta C; Gil-Gil M; Pérez-Segura P; Berrocal A; Reynés G; Gallego O; Capellades J; Ordoñez JM; La Orden B; Balañá C
    Clin Transl Oncol; 2015 Sep; 17(9):743-50. PubMed ID: 26033428
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer.
    Marth C; Vergote I; Scambia G; Oberaigner W; Clamp A; Berger R; Kurzeder C; Colombo N; Vuylsteke P; Lorusso D; Hall M; Renard V; Pignata S; Kristeleit R; Altintas S; Rustin G; Wenham RM; Mirza MR; Fong PC; Oza A; Monk BJ; Ma H; Vogl FD; Bach BA
    Eur J Cancer; 2017 Jan; 70():111-121. PubMed ID: 27914241
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors.
    Diamond JR; Wu B; Agarwal N; Bowles DW; Lam ET; Werner TL; Rasmussen E; Gamelin E; Soto F; Friberg G; Sun YN; Sharma S
    Invest New Drugs; 2015 Jun; 33(3):691-9. PubMed ID: 25895965
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma.
    Nishikawa M; Inoue A; Ohnishi T; Yano H; Kanemura Y; Kohno S; Ohue S; Ozaki S; Matsumoto S; Suehiro S; Nakamura Y; Shigekawa S; Watanabe H; Kitazawa R; Tanaka J; Kunieda T
    Cancer Med; 2021 Mar; 10(6):2013-2025. PubMed ID: 33543833
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma.
    Badruddoja MA; Pazzi M; Sanan A; Schroeder K; Kuzma K; Norton T; Scully T; Mahadevan D; Ahmadi MM
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):715-721. PubMed ID: 28808777
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcoma.
    D' Angelo SP; Mahoney MR; Van Tine BA; Adkins DR; Perdekamp MT; Condy MM; Luke JJ; Hartley EW; Antonescu CR; Tap WD; Schwartz GK
    Cancer Chemother Pharmacol; 2015 Mar; 75(3):629-38. PubMed ID: 25672915
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma.
    Lassen U; Chinot OL; McBain C; Mau-Sørensen M; Larsen VA; Barrie M; Roth P; Krieter O; Wang K; Habben K; Tessier J; Lahr A; Weller M
    Neuro Oncol; 2015 Jul; 17(7):1007-15. PubMed ID: 25665807
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab?
    Franceschi E; Lamberti G; Paccapelo A; Di Battista M; Genestreti G; Minichillo S; Mura A; Bartolini S; Agati R; Brandes AA
    J Neurooncol; 2018 Sep; 139(2):383-388. PubMed ID: 29671196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer.
    Vergote I; Schilder RJ; Pippitt CH; Wong S; Gordon AN; Scudder S; Kridelka F; Dirix L; Leach JW; Ananda S; Nanayakkara N; Melara R; Bass MB; Litten J; Adewoye H; Wenham RM
    Gynecol Oncol; 2014 Oct; 135(1):25-33. PubMed ID: 25019569
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bevacizumab: a treatment option for recurrent glioblastoma multiforme.
    Buie LW; Valgus J
    Ann Pharmacother; 2008 Oct; 42(10):1486-90. PubMed ID: 18765835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.